10:22 AM EST - Profound Medical Corp. : Announced initial perioperative data from the Level 1 post-market CAPTAIN trial comparing the safety and efficacy of the TULSA procedure with radical prostatectomy in men with organ-confined, intermediate-risk, Gleason Score 7 (Grade Group 2 and 3) prostate cancer. Profound Medical Corp.
shares T.PRN are trading up $0.10 at $6.66.
